Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Analysis of copy number variation using quantitative interspecies competitive PCR.
PMID 18697816 · PMC2553599 · Nucleic acids research · 2008 · 7 claims · 6 setups
qicPCR uses the entire genome of a single chimpanzee as a competitor, requiring only one reference sample for all assays and enabling large-scale multiplexing
-
Full-text index only
Use of proteomics for validation of the isolation process of clotting factor IX from human plasma.
PMID 19819359 · PMC2818390 · Journal of proteomics · 2010 · 8 claims · 8 setups
Proteomic techniques (LC-MS/MS, iTRAQ, immunochemical/biochemical methods) can monitor and validate each production step of pd F IX isolation
-
Full-text index only
Adaptation, aging, and genomic information.
PMID 20157529 · PMC2806027 · Aging · 2009 · 8 claims · 6 setups
Aging is caused primarily by the absence of adaptive genomic information for later-age survival and function, due to declining forces of natural selection with adult age; this absence secondarily produces misallocation and damage at every level of biological organization.
-
Has reproduction · 67
NET-prism enables RNA polymerase-dedicated transcriptional interrogation at nucleotide resolution.
PMID 31156037 · PMC6693550 · RNA biology · 2019 · 8 claims · 7 setups
NET-prism, an adapted NET-seq protocol using immunoprecipitation of Pol II-associated factors, enables strand-specific, nucleotide-resolution interrogation of transcription dynamics for any Pol II-interacting protein.
-
Full-text index only
Cancer biomarker AKR1B10 and carbonyl metabolism.
PMID 19028477 · PMC6193474 · Chemico-biological interactions · 2009 · 8 claims · 6 setups
AKR1B10 reduces the anticancer drug daunorubicin to daunorubicinol, decreasing its chemotherapeutic effectiveness